Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer?
Patients with a thyroid follicular or papillary cancer referred to radioiodine treatment in
oncological department . The patients after thyroidectomy will be treated with Liothyronine
and this treatment will be paused 10 days before radioiodine. As a routine these patients
will be re-evaluated with iodine uptake 4 months later.
The patients will be randomised to either T3 pause related to the first radioiodine
treatment and Thyrogen injection (recombinant TSH) related to the second treatment/uptake -
or Thyrogen related to the first treatment and T3 pause related to the second treatment
All medication given in the 10 days period right before radioiodine treatment/uptake will be
delivered to the patients and marked with a protocol number. In the period with T3 pause the
patients will be given placebo tablets and an injection of saline (instead of Thyrogen)
before treatment/uptake at the similar time as given the Thyrogen injection. A nurse
otherwise not involved in the study will give the injection.
Patients will be evaluated by VAS, SF-36, and Eortc QLC30 (version 2.0) before radioiodine
treatment and 3 weeks after treatment.
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
quality of life
Birte Nygaard, Md, PhD
dept of endocrinology,Herlev Hospital
Denmark: Danish Medicines Agency